PMID- 24895793
OWN - NLM
STAT- MEDLINE
DCOM- 20140619
LR  - 20151119
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 61
IP  - 129
DP  - 2014 Jan-Feb
TI  - Monocyte chemotactic protein-1 as possible prognostic markers of the efficacy of 
      antiviral treatment in chronic hepatitis C.
PG  - 55-8
AB  - BACKGROUND/AIMS: Antiviral therapy with interferon and ribavirin had been proved 
      to be effective in Hepatitis C treatment. However, the valuable markers for 
      monitoring the efficacy of antiviral therapy are required clinically. The present 
      study aimed to evaluate the association between pretreatment levels of Monocyte 
      chemoattractant protein-1 levels (MCP-1) and the virological response in treated 
      patients with chronic hepatitis C infection. METHODOLOGY: Concentrations of MCP-1 
      in serum were determined in 165 patients with chronic hepatitis C (CHC) treated 
      with interferon and ribavirin by enzyme linked immunosorbent assay before and 48 
      weeks after cessation of therapy. RESULTS: Pretreatment MCP-1 levels in patients 
      with sustained virological response (SVR) were significantly lower than in 
      non-responders (Non-SVR) (220.2 +/- 31.7 vs. 305.6 +/- 50.7 pg/mL, p = 0.009) and 
      MCP-1 significantly decreased in patients with SVR (form 220.2 +/- 31.7 pg/mL to 
      140.2 +/- 26.7 pg/mL; p <0.01) but not in Non-SVR (form 305.6 +/- 50.7 pg/mL to 
      286.6 +/- 41.9 pg/mL; p = 0.17) after 48 weeks of treatment. By multivariate 
      analysis, non-1 genotype was independent predictors of SVR in all patients. When 
      multivariate analysis was restricted to patients with non-1 genotype, only 
      pretreatment MCP-1 levels were identified as predictive factors of SVR. 
      CONCLUSIONS: MCP-1 may be a prognostic marker of the efficacy of antiviral 
      therapy in CHC patients.
FAU - Gu, Bin
AU  - Gu B
FAU - Ye, Bo
AU  - Ye B
FAU - Mao, Wei-Lin
AU  - Mao WL
FAU - Ye, Ji-Lu
AU  - Ye JL
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interferon-alpha)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood
MH  - Female
MH  - Hepatitis C, Chronic/*blood/*drug therapy
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Ribavirin/*therapeutic use
MH  - Treatment Outcome
EDAT- 2014/06/05 06:00
MHDA- 2014/06/20 06:00
CRDT- 2014/06/05 06:00
PHST- 2014/06/05 06:00 [entrez]
PHST- 2014/06/05 06:00 [pubmed]
PHST- 2014/06/20 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2014 Jan-Feb;61(129):55-8.